Sangamo Therapeutics (NASDAQ:SGMO) Price Target Raised to $10.00 at HC Wainwright

Sangamo Therapeutics (NASDAQ:SGMO - Free Report) had its price objective raised by HC Wainwright from $5.00 to $10.00 in a research note released on Tuesday morning, Benzinga reports. HC Wainwright currently has a buy rating on the biopharmaceutical company's stock.

Separately, StockNews.com started coverage on Sangamo Therapeutics in a research note on Sunday, July 28th. They set a "sell" rating on the stock. One research analyst has rated the stock with a sell rating, three have given a hold rating and one has issued a buy rating to the company's stock. According to MarketBeat, Sangamo Therapeutics currently has a consensus rating of "Hold" and a consensus target price of $4.33.

Sangamo Therapeutics Trading Up 24.1 %

Shares of NASDAQ:SGMO traded up $0.42 on Tuesday, reaching $2.16. The company had a trading volume of 9,390,785 shares, compared to its average volume of 6,779,155. Sangamo Therapeutics has a 52-week low of $0.29 and a 52-week high of $2.30. The firm's 50 day simple moving average is $1.02 and its 200-day simple moving average is $0.74. The firm has a market capitalization of $449.76 million, a PE ratio of -1.57 and a beta of 1.10.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last announced its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.01). Sangamo Therapeutics had a negative return on equity of 273.25% and a negative net margin of 2,033.69%. The business had revenue of $0.36 million for the quarter, compared to analysts' expectations of $11.40 million. As a group, equities research analysts predict that Sangamo Therapeutics will post -0.47 earnings per share for the current year.

Hedge Funds Weigh In On Sangamo Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of SGMO. Acadian Asset Management LLC grew its position in shares of Sangamo Therapeutics by 4.0% in the first quarter. Acadian Asset Management LLC now owns 4,943,260 shares of the biopharmaceutical company's stock valued at $3,311,000 after purchasing an additional 192,385 shares in the last quarter. Renaissance Technologies LLC grew its position in Sangamo Therapeutics by 58.8% in the second quarter. Renaissance Technologies LLC now owns 4,126,577 shares of the biopharmaceutical company's stock worth $1,479,000 after acquiring an additional 1,528,600 shares during the period. Marshall Wace LLP grew its position in Sangamo Therapeutics by 56.3% in the second quarter. Marshall Wace LLP now owns 576,219 shares of the biopharmaceutical company's stock worth $207,000 after acquiring an additional 207,476 shares during the period. Mirae Asset Global Investments Co. Ltd. acquired a new position in Sangamo Therapeutics during the first quarter worth $331,000. Finally, Vontobel Holding Ltd. lifted its stake in Sangamo Therapeutics by 412.3% during the third quarter. Vontobel Holding Ltd. now owns 300,000 shares of the biopharmaceutical company's stock worth $259,000 after purchasing an additional 241,440 shares in the last quarter. Institutional investors and hedge funds own 56.93% of the company's stock.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.